Signaling lymphocyte activation molecules (SLAMs) play an integral role in immune regulation. Polymorphisms in the SLAM family receptors are implicated in human and mouse model of lupus disease. The lupus-associated, somatically mutated, and class-switched pathogenic autoantibodies are generated in spontaneously developed germinal centers (GCs) in secondary lymphoid organs. The role and mechanism of B cell-intrinsic expression of polymorphic SLAM receptors that affect B cell tolerance at the GC checkpoint are not clear. In this study, we generated several bacterial artificial chromosome-transgenic mice that overexpress C57BL/6 (B6) alleles of different SLAM family genes on an autoimmune-prone B6.Sle1b background. B6.Sle1b mice overexpressing B6-derived Ly108 and CD84 exhibit a significant reduction in the spontaneously developed GC response and autoantibody production compared with B6.Sle1b mice. These data suggest a prominent role for Sle1b-derived Ly108 and CD84 in altering the GC ...
T he signaling lymphocyte activation molecule (SLAM) family receptors play critical roles in immune regulation and are required for an effective humoral response (1, 2) . The Sle1b sublocus derived from the lupus-prone NZM2410/NZW strain harbors the SLAM family (Slamf) genes (3) . Previous studies suggested that Slamf genes are major players in mediating the loss of tolerance to nuclear Ags and in the development of autoimmunity in C57BL/6 (B6).Sle1b mice (3) . Polymorphisms in the Ly108/Slamf6 gene are implicated in the loss of early B cellmediated (4), as well as peripheral T cell-mediated, tolerance (5) . Several independent studies suggested the contribution of three other SLAMF genes, Slamf1 (SLAM/CD150), Slamf2 (CD48), and Slamf3 (Ly9), in autoimmunity (6) (7) (8) . However, the role of B cellintrinsic expression of different isoforms of Ly108 or other SLAM receptors in the regulation of B cell tolerance at the germinal center (GC) checkpoint remains unclear. Elucidation of the mechanism by which SLAM receptors regulate GCs is important, because GCs develop spontaneously in autoimmune mice and humans and generate somatically mutated and class-switched pathogenic autoantibodies (9) (10) (11) .
Because Slamf genes are genetically linked, it has been difficult to determine the potential role of polymorphisms in a specific family member in autoimmunity using knockout mice generated in an autoimmune 129 background and subsequently backcrossed to B6 mice (6-8, 12, 13) . It is also unclear whether non-Slamf genes located in Sle1b contribute to a break in B cell tolerance given the presence of nonsynonymous mutations in these genes in autoimmune B6.Sle1b mice (3) . To definitively determine the role of particular Slamf and/or non-Slamf genes within the Sle1b sublocus in the development of autoimmunity and to study the mechanisms by which these genes affect B cell tolerance at the GC checkpoint, we used a bacterial artificial chromosome (BAC)-transgenic rescue approach. We generated six BAC-transgenic mouse lines expressing B6 alleles of the different genes spanning the entire Sle1b sublocus and then bred them onto B6.Sle1b mice. The B6.Sle1b BAC-transgenic mouse line containing B6 alleles of Ly108 and CD84 (designated Sle1b-BAC90) showed a significant reduction in anti-nuclear Ab (ANA) titers and positivity (penetrance) and a decreased spontaneously developed GC (Spt-GC) response, indicating a critical role for Ly108 and CD84 in maintaining GC B cell tolerance.
Both CD84 and Ly108 are essential in maintaining tolerance because B6.Sle1b BAC-transgenic mice expressing the B6 allele of Ly108 alone showed only a partial restoration of tolerance to ANA. Using a conditional deletion (Cre-LoxP) system, we showed that GC B cell-specific expression of autoimmune-prone CD84 and Ly108 genes is sufficient for the loss of B cell tolerance. B cell function assays revealed that polymorphisms in the CD84 and Ly108 proteins in B6.Sle1b B cells helped B cells escape tolerance by lowering BCR signaling, decreasing apoptosis, and attenuating B cell-T cell interactions. Normalization of B6.Sle1b-derived CD84 and Ly108 by overexpression of wild-type CD84 and Ly108 restored BCR signaling and B cell-T cell interactions. Our results highlight the vital role of GC B cell-specific Ly108 and CD84 expression and function in the maintenance of B cell tolerance at the GC checkpoint.
Materials and Methods

Mice
Breeding pairs of B6, GC B cell Cre (C.129P2[Cg]-Ighg1 tm1[IRES-cre]Cgn /J), and OT-II-transgenic (B6.Cg-Tg [TcraTcrb]425Cbn/J) mice were originally purchased from The Jackson Laboratory, and mice were bred inhouse. Derivation of B6 mice congenic for the Sle1b sublocus (named B6.Sle1b) was described previously (14) . All animals were housed in the specific pathogen-free animal facility at Penn State Hershey Medical Center, and all procedures were performed in accordance with the guidelines approved by the Pennsylvania State University College of Medicine Institutional Animal Care and Use Committee.
Generation of BAC-transgenic mice
BACs were identified from the B6-derived BAC library (BACPAC Resources, Oakland, CA). The following BACs were used: RPCI-23 194D6 (BAC41), RPCI-23 48O11 (BAC47), RPCI-23 171K8 (BAC25), RPCI-23 145F9 (BAC40), RPCI-23-388C4 (BAC90), RPCI-23 462J8 (BAC95), and RPCI-23 438K9 (BAC-Ly108). Bacterial cultures from these BAC clones were grown in Luria broth with chloramphenicol (12.5 mg/ml) overnight at 37˚C. QIAGEN Midi Kit solutions, P1, P2, and P3, were used to isolate BAC DNA (QIAGEN, Valencia, CA). The DNA was purified further by phenol-chloroform extraction, followed by cesium chloride gradient ultracentrifugation. BAC DNA was diluted to 50 ng/ml in 10 mM Tris-HCl [pH 7.5] and 0.1 mM EDTA and injected into fertilized oocytes derived from B6 mice. Founder lines were identified by PCR specific for the vector ends and then bred onto the respective genetic backgrounds.
Generation of floxed BAC90 mice
The BAC (RPCI-23-388C4) used to generate floxed BAC90 mice was purchased from BACPAC Resources. The BAC vector backbone already contained LoxP sites that flanked the insert (B6-derived CD84 and Ly108). No additional manipulation was made to the backbone. BAC vector DNA amplification, purification, and injection into B6-derived fertilized oocytes were performed as described above ("Generation of BACtransgenic mice").
Flow cytometry
The following Abs were used for flow cytometric analysis of mouse splenocytes or bone marrow (BM) cells. Pacific Blue-anti-B220 (RA3-6B2), Alexa Fluor 700-anti-CD4 (RM4-5), PE-anti-PD-1 (29F.1A12), PerCP-Cy5.5-anti-CD69 (H1.2F3), allophycocyanin-Cy7-anti-CD25 (PC61), Cy5-anti-CD86 (GL1), PE-Cy7-anti-CD95 (FAS, Jo2), PE-Cy7-anti-MHC class II (M5/114.15.2), allophycocyanin-anti-CD24 (HSA) (M1/69), biotinanti-Ly5.1 (BP-1) (6C3), FITC-anti-CD23 (B3B4), and PE-Cy5-streptavidin (SA) were from purchased from BioLegend (San Diego, CA). Biotinanti-CXCR5 (2G8) was purchased from BD Pharmingen (San Diego, CA). FITC-peanut agglutinin (PNA) was purchased from Vector Labs (Burlingame, CA). PE-anti-IgM (eB121-15F9), allophycocyanin anti-CD93 (AA4.1), and FITC-anti-F4/80 (BM8) were purchased from eBioscience (San Diego, CA). The following Abs were used for phosphoflow analysis of purified mouse B cells: PE-anti-Btk (pY223)/ItK (pY180) (N35-86), Alexa Fluor 647-anti-ERK1/2 (pT202/pY204) (20A), Pacific Blue-anti-p38 MAPK (pT180/pY182), and Alexa Fluor 488-anti-Syk (pY348) (I120-722). Stained cells were analyzed using a BD LSR II flow cytometer (BD Biosciences, Franklin Lakes, NJ). Data were acquired using FACSDiva software (BD Biosciences, San Jose, CA) and analyzed using FlowJo software (TreeStar, San Carlos, CA).
Immunohistology
The following Abs and reagents were used for immunohistochemical analysis of mouse spleen sections: PE-anti-CD4 (GK1.5), FITC-GL7, and allophycocyanin-anti-IgD (all from BD Biosciences). Spleen cryostat sections (5-6 mm) were prepared as previously described (15) . Immunohistochemistry was performed as described (15) , and stained sections were analyzed with a Leica DM4000 fluorescence microscope and Leica software (Leica Microsystems, Buffalo Grove, IL). The color intensity of the images was enhanced slightly using Adobe Photoshop CS4 (Adobe Systems, San Jose, CA) for better visualization; it was carried out consistently among all sections while maintaining the integrity of the data.
ELISPOT assays
ELISPOT assays were performed as previously described (16) . Briefly, splenocytes in 10% RPMI 1640 were plated at a concentration of 1 3 10 5 cells/well onto anti-IgM-coated or anti-IgG-coated (Invitrogen, Grand Island, NY) multiscreen 96-well filtration plates or at a concentration of 1 3 10 6 cells/well on dsDNA-, histone-, or nucleosome-coated multiscreen 96-well filtration plates (Millipore, Bedford, MA). Serially diluted (1:2) cells were incubated for 6 h at 37˚C. IgM-producing Ab-forming cells (AFCs) were detected using biotinylated anti-mouse IgM (Jackson ImmunoResearch, West Grove, PA) and SA-alkaline phosphatase (Vector Laboratories, Burlingame, CA). IgG-producing AFCs were detected using alkaline phosphatase-conjugated anti-mouse IgG (Molecular Probes, Grand Island, NY). dsDNA-, histone-, and nucleosome-specific AFCs were detected by biotinylated anti-k Ab (Invitrogen, Grand Island, NY) and SAalkaline phosphatase (Vector Laboratories) or alkaline phosphatase-conjugated anti-mouse IgG (Molecular Probes, Grand Island, NY). Plates were developed using the Vector Blue AP Substrate Kit III (Vector Laboratories). ELISPOTs were enumerated and analyzed using a computerized imaging/analysis system (Cellular Technology, Shaker Heights, OH).
Serology: Ig and autoantibody titers
ELISA plates were coated with anti-IgM or anti-IgG capture Abs (Invitrogen) and detected using biotinylated anti-mouse IgM (Jackson ImmunoResearch) or alkaline phosphatase-conjugated anti-mouse IgG (Molecular Probes). Total IgG autoantibody titers were measured in ELISA plates coated with dsDNA, histone, nucleosome, Smith/ribonucleoprotein (Sm/RNP), or cardiolipin and detected with biotinylated anti-k Ab (Invitrogen). IgG subtypespecific autoantibody titers were detected by biotinylated IgG1, biotinylated IgG2b, and alkaline phosphatase-IgG2c Abs (Southern Biotech, Birmingham, AL). Biotinylated Abs were detected by SA-alkaline phosphatase (Vector Laboratories). The plates were developed using PNPP (disodium salt; Thermo Fisher Scientific, Rockford, IL) substrates for alkaline phosphatase.
In vitro B cell-proliferation assay
Naive B cells were purified from the indicated mice with mouse anti-CD43 (Ly-48) MicroBeads. Purified B cells were stained with 3 mM CFSE (Sigma-Aldrich, St. Louis, MO) in PBS with 5% FBS for 15 min at room temperature. Stained B cells were cultured with 25 mg/ml soluble anti-IgM (Jackson ImmunoResearch) and 20 mg/ml soluble anti-CD40 Ab (BioLegend). After 72 h of stimulation, cells were acquired using a BD LSR II flow cytometer.
and Fluo-3 (5 mM) (Invitrogen) in dyeless RPMI 1640 (Mediatech) for 45 min at 37˚C. A baseline calcium reading was acquired for 1 min before the addition of 5 or 10 mg/ml anti-IgM (Jackson ImmunoResearch), followed immediately by a 3-min acquisition through the BD LSR II flow cytometer.
B cell-T cell in vitro conjugate assay Naive B cells from each indicated group of mice were purified with mouse anti-CD43 (Ly-48) MicroBeads, stained with 5 mM CellTrace Violet (Invitrogen), and activated with 25 mg/ml soluble anti-IgM and 1 mg/ml LPS for 24 h at 37˚C. Naive T cells from OT-II-transgenic mice were purified with a pan-T isolation kit (Miltenyi Biotec), stained with 3 mM CFSE, and activated with 10 mg/ml anti-CD3 and 2 mg/ml anti-CD28 for 24 h at 37˚C. A total of 10 mg/ml OVA peptide (InvivoGen, San Diego, CA) was added to the B cells 3 h prior to the start of the assay. A total of 1 3 10 6 B cells and 1 3 10 6 T cells were placed together for the stipulated times, fixed with 4% paraformaldehyde, and acquired using a BD LSR II.
Phosphoflow analysis
Splenocytes isolated from each indicated mouse group were activated with 25 mg/ml anti-IgM for the indicated times at 37˚C. Following activation, cells were fixed with Lyse/Fix (BD) for 10 min at 37˚C. Following washes, cells were permeabilized with Perm/Wash Buffer (BD) for 30 min at room temperature. Following two washes with Perm/Wash Buffer, cells were stained for anti-B220 and phosphoflow Abs (BD) described above for 1 h. Samples were acquired using a BD LSR II flow cytometer.
Assessment of GC sizes
Immunohistochemistry was performed using the Abs listed in the "Immunohistology" section, and stained sections were analyzed with a Leica DM4000 fluorescence microscope and Leica software (Leica Microsystems). Ten randomly selected GCs/mouse from the indicated mouse groups (five mice from each group) were assessed for total area (mm 2 ) using Leica Microsystems software.
In vitro B cell-functional assays B cells were purified from naive B6, B6.Sle1b, or Sle1b-BAC90 mice with mouse anti-CD43 (Ly-48) MicroBeads, stimulated with 25 mg/ml antiIgM, 10 mg/ml anti-CD40, and/or 5 mg/ml anti-Ly108 (13G3-19D) (eBioscience) or 2 mg/ml recombinant CD84 agonist (R&D Systems) for 24 h, and acquired using a BD LSR II flow cytometer.
DNA/RNA preparation and real-time RT-PCR
Total DNA was isolated with a DNeasy Blood and Tissue kit (QIAGEN, Hilden, Germany), following the manufacturer's guidelines, from the tails of the indicated mice. Gene expression was quantified using TaqMan Master Mix and the StepOnePlus Real-Time PCR system (Applied Biosystems, Grand Island, NY). Primers for CD84 and Ly108 copy number assay were purchased from Life Technologies. Amplification conditions for all primer sets were 1 cycle at 95˚C for 10 min, followed by 40 cycles at 95˚C for 15 s and 60˚C for 1 min. Mouse Tert was used as the reference gene.
Total RNA was isolated from purified B cells and T cells or from GC B cells and follicular helper T cells (Tfh cells) sorted with a FACSAria Sorter using the RNeasy Mini Kit (QIAGEN), following the manufacturer's guidelines. RNA was reverse transcribed using the High-Capacity Reverse Transcription kit (Applied Biosystems). Gene expression was quantified using TaqMan PCR Master Mix kit or Power SYBR Green PCR Master Mix Kit using the StepOnePlus Real-Time PCR System (all from Applied Biosystems). Primers for the SLAM genes were purchased from Life Technologies, and Ly108 isoform primers were designed using Primer3 software and synthesized by IDT Technologies (Coralville, Iowa). The following primer sequences were used: Ly108.1: forward 59-CTCGT-CCAATGCAGGAAATG-39 and reverse 59-AGATGTGTTCTCCCTGGA-TTTC-39; Ly108.2: forward 59-CTCGTCCAATGCAGGAAATG-39 and reverse 59-AGGAGTTATAGTTGATTAAG-39; and Ly108-H1: forward 59-AGCACAGATGGCCCAGG-39, reverse 59-AGGAGTTATAGTTGAT-TAAAG-39. Amplification conditions for all primer sets were 1 cycle at 95˚C for 10 min, followed by 40 cycles at 95˚C for 15 s and 60˚C for 1 min. GAPDH was used as the reference gene for sample normalization.
Extracellular flux analysis
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured in a XF96 extracellular flux analyzer using a kit, as per manufacturer's instructions (Seahorse Bioscience, Boston, MA). Briefly, B cells from B6, B6.Sle1b, and Sle1b-BAC90 mice were purified by negative selection using CD43 MicroBeads by MACS purification (Miltenyi Biotec). Purified B cells were stimulated with 25 mg/ml anti-IgM and 20 mg/ml anti-CD40 for 18 h in RPMI 1640 + 10% FCS. Thereafter, 6 3 10 5 activated B cells were plated in XF media (Seahorse Bioscience) with 25 mM glucose onto a Cell-Tak (BD Biosciences)-coated XF96 plate. Oligomycin (1 mM), carbonyl cyanide 4-(trifluoromethoxy) phenyl hydrazone (2 mM), rotenone (1 mM), and antimycin (1 mM) were added sequentially, and measurements of extracellular flux were recorded. Glycolysis was calculated from ECAR values at the basal respiration phase, and glycolytic capacity was calculated from ECAR values after the inhibition of ATP synthase by the addition of oligomycin, when cells resort to meeting their energy demands using their maximum glycolytic capacity. OCR and ECAR data were analyzed using Wave software and plotted using GraphPad Prism v6.0 (La Jolla, CA).
Two-dimensional live cell microscopy, image acquisition, and cell-tracking analysis
For the live cell-tracking measurements, the confocal technique (Leica AOBS SP8 laser scanning confocal microscope; Leica Microsystems, Heidelberg, Germany) was used along with a heated live cell stage equipped with a humidified 5% CO 2 perfusion system (TOKAI HIT). The live cell data mode (xyt) in the image-acquisition software (Leica Confocal Software LAF) was used for the two-dimensional (2D) imaging of live cells. Activated B cells loaded with OVA peptide and labeled with CellTrace (Invitrogen) were mixed with activated CFSE-labeled OT-II T cells in 0.5 mg/ml collagen solution, pH 7 (TelCol, type 1 acid-soluble collagen solution from Advanced BioMatrix, San Diego, CA). 2D live cell images of B and T cell contacts were acquired sequentially using the 633/1.2 high numerical aperture apochromatic waterimmersion objective every 30 s for 1 h. The laser lines for excitation included UV diode, 80 MHz white light laser (Leica AOBS SP8 module), and the emission signals were collected sequentially using AOBS tunable filters to eliminate cross-talk and cross-excitation. All of the fluorescent images, as a function of time, were collected using highly sensitive HyD detectors (with time gated option). The images (8 bit) were line-averaged to minimize the random noise, and a pixel format of 512 3 512 was selected. For each sample, 2D time-series images were compiled, and cell tracking was performed using Imaris and Imaris XT (Bitplane, Switzerland) functions, based on the Matlab program. The data were compiled in Microsoft Excel (Microsoft, Redmond, WA) sheets, and final plots, slope measurements, and statistical analysis were performed using GraphPad Prism v6 or Origin Lab v9.1.
Statistical analysis
Unpaired, nonparametric, Mann-Whitney, and Student t tests were used for comparing two groups, and one-way ANOVA followed by Tukey's multiple comparison test was used for comparing more than two groups. GraphPad Prism 6 analytical tool (La Jolla, CA) was used for every analysis. Wherever indicated, NS = nonsignificant, *p # 0.05, **p # 0.01, ***p # 0.001, and ****p # 0.0001. Error bars reflect mean values, unless otherwise noted.
Results
A major role for SLAM family receptors CD84 and Ly108 in maintaining tolerance SLAM family genes, located in the telomeric end of chromosome 1 in autoimmune mice (i.e., NZM2410/NZW-derived Sle1b interval) and human systemic lupus erythematosus patients, are implicated in altering B cell tolerance (3, (16) (17) (18) . To definitively determine the contribution of particular Slamf genes within the Sle1b sublocus in autoimmunity, a panel of B6-derived BACs spanning the entire Sle1b interval was used to generate a series of transgenic mouse lines (Fig. 1A) .
Multiple founder lines carrying different copy numbers were generated for each BAC (Fig. 1A) . Of the six BAC-transgenic mouse lines generated, only the BAC transgene carrying B6 alleles of CD84 and Ly108 (referred to as BAC90) was able to significantly suppress both ANA positivity/penetrance (Fig. 1B) and titers (Fig. 1C) when bred to B6.Sle1b mice (referred to as Sle1b-BAC90). The BAC transgene carrying 2B4 (Slamf4), Ly9 (Slamf3), and Cs1 (Slamf7) (referred to as BAC25) also had lower ANA titers (Fig. 1C) , but 70% of B6.Sle1b mice expressing the BAC25 transgene (designated Sle1b-BAC25) remained positive for ANA (Fig. 1B) . When we analyzed ANA titers in B6.Sle1b mice expressing each founder line for a given BACtransgenic strain, we did not find a significant difference among the individual founder lines, with the exception of BAC25 and BAC90 (Supplemental Fig. 1 ). Of the three BAC90-transgenic founder lines generated, two (BAC90-4389 and BAC90-4390) had significantly lower ANA titers than the third (BAC90-4270). A significant difference in ANA titers was observed between BAC90-4270 and BAC90-4389 lines (Supplemental Fig. 1) . We also observed a difference between the two BAC25 lines (Supplemental Fig. 1 ).
To determine whether Ly108 alone was able to mediate the suppression of ANA production in Sle1b-BAC90 mice, a BACtransgenic mouse carrying only the B6 allele of Ly108 was generated and bred onto the B6.Sle1b background (referred to as Sle1b-BAC-Ly108). Sle1b-BAC-Ly108 mice displayed a reduction in serum ANA penetrance and titers (Supplemental Fig. 2 ), but not to the extent that was observed in aged Sle1b-BAC90 mice that carry both CD84 and Ly108 (Fig. 1B, 1C ). These data indicate that allelic variations in both CD84 and Ly108 were required to break tolerance to nuclear self-Ags in B6.Sle1b mice.
Restoration of B cell tolerance at the GC checkpoint by overexpression of B6-derived CD84 and Ly108
Sle1b alters peripheral B cell tolerance at the GC checkpoint, leading to elevated Spt-GC and Tfh cell responses (16) . We asked whether introduction of the B6 wild-type alleles of CD84 and Ly108 into B6.Sle1b mice could restore tolerance by regulating the GC checkpoint in B6.Sle1b mice. We first evaluated the surface expression and found that CD84 and Ly108 levels were higher in B cells from B6.Sle1b and Sle1b-BAC90 mice compared with B6 mice at 2 mo of age (Supplemental Fig. 3A) . However, B6.Sle1b B cells exhibited a significant reduction in both CD84 and Ly108 surface expression by 8 mo compared with B6 and Sle1b-BAC90 B cells (Supplemental Fig. 3B) . A similar temporally biphasic expression profile for CD84 and Ly108 was observed when GC B cells were analyzed at 2 and 8 mo of age (data not shown). CD84 expression on CD4 + T cells remained similar among the three strains, but Ly9 and Ly108 levels on CD4 + T cells were higher in B6.Sle1b and Sle1b-BAC90 mice than in B6 mice at both 2 and 8 mo of age (data not shown). We observed no difference in SLAM adaptor (SAP) molecule transcript levels in B cells and T cells from these mice (data not shown).
Immunohistological analysis of spleens revealed smaller and less frequent Spt-GCs in B6 and Sle1b-BAC90 mice compared with B6.Sle1b mice (Fig. 2A, 2B ). This decrease in Spt-GCs was confirmed by flow cytometric analysis of splenocytes, which showed a significant reduction in the percentage of B220 +   Fas   hi   PNA hi Spt-GC B cells in 6-8-mo-old Sle1b-BAC90 female mice compared with age-matched B6.Sle1b females (Fig. 2C ). There was a strong inverse correlation between the percentage of GC B cells and the levels of Ly108 and CD84 expression on GC B cells (data not shown hi central memory T cells, all of which were significantly lower than in B6.Sle1b mice (Fig. 2D, 2E ). These data suggest the cooperative function of CD84 and Ly108 in maintaining GC B cell tolerance.
Wild-type CD84 and Ly108 prevent development of ANA-specific AFCs and serum autoantibody titers Next, we asked whether the reduction in Spt-GC responses in Sle1b-BAC90 mice resulted in decreased ANA-specific AFCs and Ab titers. B6 and Sle1b-BAC90 mice had significantly lower numbers of dsDNA-, histone-, and nucleosome-specific AFCs in the spleen (Fig. 3A-C) , as well as total serum IgM and IgG titers (Fig. 3D,  3E) , than did B6.Sle1b mice. Sle1b-BAC90 mice also exhibited significantly reduced levels of IgG2c-specific Abs against dsDNA, histone, nucleosome (Fig. 3F-H) , Sm/RNP, and cardiolipin (Fig. 3J,  3K ) as well as IgG2b-specific anti-nucleosome Abs (Fig. 3I ) compared with B6.Sle1b mice. The reduced autoantibody levels in Sle1b-BAC90 mice strongly correlated with the lower percentage of Spt-GC B cells (data not shown).
The cardinal function of GCs is the generation of long-lived AFCs, which primarily reside in BM (19) . We asked whether elevated Spt-GC and Tfh cell responses in B6.Sle1b mice resulted in more ANA-specific, long-lived BM AFCs and whether the elevated ANA-specific BM AFC response in B6.Sle1b mice could be reversed by the introduction of B6 alleles of CD84 and Ly108 in Sle1b-BAC90 mice. Although there were significantly higher numbers of ANA-specific AFCs in the BM of B6.Sle1b mice, their numbers were markedly reduced in Sle1b-BAC90 mice (Fig. 3L-N) . The reduction in Spt-GC, Tfh cell, and ANA responses in Sle1b-BAC90 mice was not the result of global suppression of the ability of B cells to mount an immune response, because no differences were observed in the foreign Ag-specific GC, Tfh cell, and Ab responses among B6, B6.Sle1b, and Sle1b-BAC90 mice immunized with SRBCs (data not shown). 
Overexpression of B6-derived CD84 and Ly108 on GC B cells is sufficient to restore tolerance in B6.Sle1b mice
To determine whether the overexpression of B6 alleles of CD84 and Ly108 within GC B cells could restore tolerance, we generated Sle1b-BAC90 fl/fl mice and crossed them with GC B cell-specific Cg-Ighg1-Cre mice (20, 21) . Quantitative PCR analysis of gene copy number and flow cytometric analysis of surface expression confirmed significantly reduced expression levels of the Ly108 and CD84 genes, specifically in GC B cells (Fig. 4A-D) and not in non-GC naive B cells (data not shown), confirming GC B cellspecific deletion of the BAC90 transgene containing B6-CD84 and Ly108 genes in Sle1b-BAC90 controls ( Fig. 4E-H) . These elevated responses in Sle1b-BAC90
fl/fl -Cre mice were similar to the increased responses seen in B6.Sle1b mice (Fig. 4E-H) . Immunofluorescent staining of spleen sections with GL7, anti-IgD, and anti-CD4 confirmed the flow cytometry data, showing increased numbers and sizes of IgD 2 GL7 + Spt-GCs in B6.Sle1b and Sle1b-BAC90 fl/fl -Cre mice compared with B6 and Sle1b-BAC90 fl/fl controls (Fig. 4I, 4J ). This increase in Spt-GC responses in Sle1b-BAC90 fl/fl -Cre mice resulted in elevated numbers of IgM-, IgG-, dsDNA-, histone-, and nucleosome-specific AFCs in the spleen (Fig. 5A-E) , as well as serum IgG2c titers specific for dsDNA, histone, nucleosome, Sm/RNP, and cardiolipin ( Fig. 5F-J) . Cre-mediated excision of transgenically expressed wild-type Ly108 and CD84 from GC B cells in Sle1b-BAC90 fl/fl -Cre mice resulted in elevated numbers of IgM-, IgG-, dsDNA-, histone-, and nucleosome-specific longlived AFCs in the BM (Fig. 5K-O) , confirming that GC B cellspecific B6 wild-type CD84 and Ly108 expression was sufficient for the restoration of tolerance in B6.Sle1b mice.
Wild-type CD84 and Ly108 expression normalizes BCR signaling, proliferation, and apoptotic capacity of B cells in B6.Sle1b mice Next, we determined whether elevated Spt-GC responses in B6.Sle1b mice compared with B6 controls correlated with increased proliferation of B cells that can potentially drive the autoimmune response. In vitro stimulation of B cells with anti-IgM and anti-CD40 unexpectedly resulted in a reduced number of proliferating B cells at 72 h in B6.Sle1b mice compared with B6 controls (Fig. 6A) . Moreover, a significantly higher percentage of B cells remained in the G 0 /G 1 phase in B6.Sle1b mice, resulting in a lower fraction of cells in the S phase compared with B6 controls (Fig. 6B) . This reduced proliferation in B6.Sle1b mice was corrected in Sle1b-BAC90 mice overexpressing B6-CD84 and Ly108 (Fig. 6A, 6B ). In line with the lower proliferation rate, stimulation with anti-IgM caused a lower Ca 2+ flux in B6.Sle1b B cells than in B6 B cells (Fig. 6C) . Notably, Sle1b-BAC90 mice exhibited a Ca 2+ flux that was similar to B6 mice (Fig. 6C) , highlighting a potential cross-talk between BCR and SLAM signaling.
Next, to determine whether the decrease in proliferative capacity of B6.Sle1b B cells resulted in increased apoptosis of B6.Sle1b B cells, we evaluated B cell survival upon stimulation. In vitro stimulation of B cells with anti-IgM and anti-CD40 resulted in a lower percentage of apoptotic B6.Sle1b B cells compared with B6 and Sle1b-BAC90 B cells (Fig. 6D) (Fig. 6E) . Overall, the percentage of apoptotic GC B cells in Sle1b-BAC90 mice was higher than in B6.Sle1b mice, but the difference was not statistically significant (Fig. 6E) . We observed no significant difference in the percentage of apoptotic GC B cells between B6 and Sle1b-BAC90 mice. Consistent with this finding, staining for apoptotic TUNEL + cells on spleen sections showed fewer apoptotic cells/mm 2 of GC area in B6.Sle1b mice than in B6 and Sle1b-BAC90 mice (Fig. 6F ). Supporting the above findings, our gene-expression analysis revealed significant upregulation of several antiapoptotic genes in B6.Sle1b B cells compared with B6 B cells (Table I) .
To determine whether there were defects in the BCR signaling pathway in B6.Sle1b B cells, we evaluated the phosphorylation status of BCR proximal signaling molecules (BTK and Syk) and downstream molecules (p-38-MAPK and Erk) after BCR activation with anti-IgM using phosphoflow analysis. Consistent with the Ca 2+ flux results, B6.Sle1b B cells exhibited decreased phosphorylation of all of these molecules (Fig. 6G-J) . Introduction of the B6 alleles of CD84 and Ly108 in Sle1b-BAC90 mice rescued this signaling defect, further supporting the possibility of cross-talk between BCR and SLAM signaling and indicating a role for Ly108 and CD84 in the restoration of peripheral B cell tolerance. Our results also show that B cells from B6.Sle1b mice were not anergic and that the reduced signaling activity exhibited by these B cells was not due to primary B cell developmental defects (Supplemental Fig. 4) .
Several genes encoding enzymes required for various metabolic pathways, including those involved in cellular energy metabolism, are modulated by the activation of B cells through BCR, CD40L, and TLR ligands (22) . Additionally, it was demonstrated that signaling events, which lead to variations in cellular energy metabolism during GC reactions, are necessary for the maintenance and differentiation of GC B cells and plasma cells (21) . Given the aforementioned differences in BCR signaling (Fig. 6G-J) , we then asked whether B cells from B6, B6.Sle1b, and Sle1b-BAC90 mice were metabolically different in responding to energy demands upon activation. No significant differences were observed in the baseline oxygen consumption among B cells from B6, B6.Sle1b, and Sle1b-BAC90 mice following activation with anti-IgM and anti-CD40 (Fig. 6K, 6L ). ATP production after exposure to oligomycin also was comparable among these three strains (Fig. 6K,  6L ). In addition, B6 and B6.Sle1b B cells showed similar maximum respiration, whereas Sle1b-BAC90 B cells showed marginally reduced maximal respiration, compared with B6 controls (Fig. 6K, 6L) . Notably, B6.Sle1b and Sle1b-BAC90 B cells had significantly higher glycolysis and glycolytic capacity than did B6 B cells (Fig. 6M, 6N ). These results indicate that reduced calcium mobilization and decreased BCR signaling in B6.Sle1b B cells did not dampen the energy metabolism in these cells.
Sle1b-expressing B cells have a lower frequency of conjugate formation with wild-type T cells, which is reversed by the overexpression of wild-type CD84 and Ly108
Previous studies showed that SAP expression in T cells is required for effective B and T cell conjugation leading to optimal GC responses during T cell-dependent antigenic stimulation or viral infection (23, 24) . The effect of B cell-intrinsic expression of lupus-associated SLAM family receptors on conjugate formation in the context of autoimmunity is not clear. We asked whether polymorphic SLAM expression in B cells from B6.Sle1b mice led to differential interaction with T cells, affecting their ability to form B cell-T cell conjugates. We further asked whether overexpression of B6-derived CD84 and Ly108 in B6.Sle1b B cells could normalize such potential differences in the ability of B6.Sle1b B cells to form conjugates with T cells.
with B cells from B6 mice; this was corrected when B cells were from Sle1b-BAC90 mice (Fig. 7A) .
To track B cell-T cell interactions in real time, 2D confocal images of conjugates between activated B cells and OT-II T cells were acquired sequentially every 30 s for 60 min (Fig. 7B, 7C) . Consistent with the flow cytometry data, the percentage of B cell-OT-II T cell conjugates was significantly lower over time when B cells were from B6.Sle1b mice compared with B6 or Sle1b-BAC90 mice (Fig. 7D, left panel) . We also measured the duration of contacts between OT-II T cells and B cells from each strain over a 60-min period. We found similar B cell-T cell contact duration time between B cells from B6 and B6.Sle1b mice. The contact duration time was higher with B cells from Sle1b-BAC90 mice compared with B6 and B6.Sle1b mice (Fig. 7D, right panel) .
Phosphoflow analysis of B cells after conjugate formation with OT-II T cells showed similar phosphorylation levels of BTK and p38-MAPK among all three strains (Fig. 7E, 7H ) but reduced phosphorylation of Erk and Syk in B cells from B6.Sle1b mice compared with B6 and Sle1b-BAC90 mice (Fig. 7F, 7G ). These data suggest that differential expression of CD84 and Ly108 on B cells could alter B and T cell interactions, resulting in reduced BCR signaling. It is plausible that such variations in the frequency of B and T cell interactions and lower BCR signaling might allow autoimmune B cells to escape the GC tolerance checkpoint.
Discussion
Polymorphisms in SLAM family genes are implicated in both murine and human lupus (1, 2, 17, (25) (26) (27) . Using B6.Sle1b mice that express the NZM2410/NZW lupus strain-derived SLAM family genes, we showed previously that this sublocus alters B cell tolerance at the GC checkpoint, leading to increased ANA-specific AFCs and ANA titers (3, 16) . However, the mechanisms by which B cell-intrinsic expression of polymorphic SLAM family genes may alter B cell tolerance at the GC checkpoint and the SLAM family members required for mediating this process were not These antiapoptotic genes were significantly upregulated in sorted B cells derived from 3-mo-old B6.Sle1b mice, as determined by Illumina Bead Chip arrays (Mouse WG-6 V2). Gene expression is shown in terms of increased fold change in B6.Sle1b mice compared with B6 controls. Statistical analysis was performed using the pairwise homogeneous t test. addressed. In this study, by analyzing seven B6.Sle1b mouse lines carrying various BAC transgenes of B6 alleles of SLAM and non-SLAM family genes spanning the entire Sle1b locus, we identified that Ly108 and CD84 play essential roles in the loss of B cell tolerance in B6.Sle1b mice. Overexpression of B6 wild-type CD84 and Ly108 can restore B cell tolerance at the GC checkpoint, leading to reduced numbers of ANA-specific long-lived AFCs in BM. Subsequently, taking advantage of GC B cell-specific Cre mice in which Cre conditionally removed transgenically expressed B6 alleles of CD84 and Ly108 on GC B cells, we further demonstrate that the expression of polymorphic CD84 and Ly108 on GC B cells is critical for the loss of tolerance to nuclear Ags in B6.Sle1b mice. These results highlight the importance of CD84 and Ly108 expression on GC B cells in regulating Spt-GC and Tfh cell responses and in preventing autoimmunity.
Our in vitro functional assays revealed lower Ca 2+ flux, reduced proliferation, and apoptosis of B cells expressing Sle1b compared with B6, all of which were restored in Sle1b-BAC90 mice overexpressing B6 alleles of CD84 and Ly108. Consistent with these data, we found reduced levels of phosphorylation of several molecules in the BCR signaling pathway in B cells from B6.Sle1b mice, whereas B6 and Sle1b-BAC90 mice showed comparable levels of phosphorylation of these molecules. Our results are consistent with a previous report (4) The mechanism by which autoreactive B cells in B6.Sle1b mice are selected into autoantibody-producing long-lived AFCs or memory B cells is not clear. Based on our data showing reduced proliferation and apoptosis of B cells expressing Sle1b and the reversal of these phenotypes with overexpression of B6-derived CD84 and Ly108, we suggest that the increased spontaneous GC, Tfh cell, and long-lived AFC responses in B6.Sle1b mice may not be the result of an enhanced positive selection of autoreactive B cells in GCs. Rather, we believe that autoreactive B cell development in GCs of B6.Sle1b mice is due to altered negative selection of GC B cells. We propose two plausible mechanisms by which polymorphic SLAM expression in B cells from B6.Sle1b mice may help autoreactive B cells escape negative selection in GCs. One mechanism is that polymorphic SLAM expression in B6.Sle1b B cells helps to reduce BCR signaling upon engagement of self-Ags, which allows these cells to survive in the GC and not undergo negative selection.
We propose a second scenario whereby GC B cells interact with T cells. Given the increased frequency of Tfh cells in B6.Sle1b mice, the chances of B cell-T cell interactions in GCs are very high. Therefore, given our data from the conjugate assay, we suggest that reduced B cell-T cell conjugates, resulting from B cell-intrinsic expression of polymorphic SLAMs, helps to maintain reduced BCR signaling in B cells expressing Sle1b. On one hand, this differential frequency of interaction of B6.Sle1b B cells with T cells may help autoreactive B cells to escape negative selection in GCs by reducing BCR signaling; on the other hand, it provides sufficient survival signals to these B cells to proliferate (albeit at a slower rate than B6 controls) and differentiate into autoantibody-producing AFCs. Consistent with this idea, we previously observed augmented GC responses of DNA and p-azophenylarsonate dual-reactive B cells from Ig V H knockin mice (named HKIR) expressing Sle1b (16). Under nonautoimmune conditions, because of their DNA reactivity, HKIR p-azophenylarsonate-DNA dual-reactive B cells are negatively regulated in GCs, presumably by the GC tolerance checkpoint (28) (29) (30) . However, autoimmune susceptibility, as in B6.Sle1b mice, alters their negative selection in GCs (16) . Recently, Sinai et al. (31) also reported that altered B and T cell interactions were responsible for an increased GC B cell phenotype in vitro in autoimmune-prone B6.Sle1b mice.
Anergic B cells have arrested development, are excluded from B cell follicles, and are unable to mobilize calcium (32) . Anergic B cells are also unable to proliferate, upregulate activation markers, mediate BCR signaling, or mount an immune response after BCR engagement (32) . Our results show that B6.Sle1b B cells exhibit normal B cell development in the BM and spleen, are present in B cell follicles, and seed GCs; thus, they do not exhibit an anergic state. Analysis of the cellular energy metabolism also indicates that reduced calcium mobilization and lower BCR signaling upon stimulation of B6.Sle1b B cells do not dampen the energy metabolism in these cells. B6.Sle1b B cells appear to be comparable, if not better, in responding to the high-energy demands upon activation. In a recent comparative analysis, Rathmell and colleagues (33) found that anergic B cells were metabolically suppressed, whereas B cells from autoimmune BAFF-transgenic mice were metabolically more active with increased glycolytic efficiency, which was necessary for autoantibody production. This study is in line with our data showing that B6.Sle1b B cells are not anergic; rather, they can undergo optimal metabolic reprogramming upon activation to produce high titers of autoantibodies.
The functional and mechanistic roles of Ly108 and CD84 in the context of GCs are unclear. Ly108 was proposed to act as a molecular rheostat that determines the stringency with which autoreactive B cells are purged during primary development (4), whereas other studies suggested similar functions for Ly108 in T cells (5, 34) . Although our data indicate that polymorphisms in CD84 and Ly108 in B cells determine the efficiency of tolerance, we cannot exclude a possible contribution of Ly108 expression by T cells, particularly with respect to the production of IFN-g (35) . IFN-g was demonstrated to drive pathogenic accumulation of Tfh cells in Roquin san mice and promote Ab class switching to pathogenic IgG2c, both of which are observed in B6.Sle1b mice (36) (37) (38) .
Although CD84 and Ly108 were demonstrated to be integral for optimal GC responses against protein immunization (23) , no such defect was observed in mice deficient in CD84 in the context of an acute lymphocytic choriomeningitis virus or vaccinia virus infection (24) . Our analysis also revealed no defect in spontaneous or SRBC-induced GC and Tfh cell responses in mice deficient in either CD84 or Ly108 (data not shown). These data indicate redundancy in functions of SLAM family receptors; however, these earlier studies did not investigate the B cell-intrinsic expression of polymorphic CD84 and Ly108 in the Spt-GC response. Our data suggest that CD84 and Ly108 function in a regulatory capacity in B cells, because Spt-GC responses correlated inversely with CD84 and Ly108 expression, specifically on GC B cells (data not shown). In addition, in vitro stimulation with anti-Ly108 resulted in increased CD84 levels on activated B6 B cells, which was defective in Sle1b B cells but mostly restored in Sle1b-BAC90 B cells (data not shown), indicating that the functions of these two SLAM family genes may be tightly linked. These data suggest that altered signaling in B cells mediated by Sle1b-derived CD84 and Ly108 may lead to a modulation in B and T cell interactions and subsequent selection in GCs. Consistent with this idea, we observed impaired B and T cell conjugation when B cells expressed Sle1b, which was restored by B cell expression of wild-type CD84 and Ly108.
Earlier studies focused on SLAM signaling in T cells and NKT cells owing to the discovery of the SAP molecule, which is highly expressed in these cell types (2) . SAP regulates T cell-mediated help (39) , Tfh cell development (40) , cytokine production (41), and GC response (42) . SAP expression in T cells, but not in B cells, is required for a humoral immune response (43) . Ly108 also was shown to regulate T cell signaling via the SAP-Fyn pathway (34) . Crotty and colleagues (24) further suggested that Ly108 regulates T cell and B cell interactions by modulating the ratio of positive/ negative signals mediated by SAP and SHP-1. The requirement for SAP and T cells in autoimmune responses also was described in lupus-prone MRL-FAS lpr (44) , Sanroque (45) , and B6.Sle1b mice (46) .
Although previous studies highlighted the importance of SLAM-SAP signaling within T cells in shaping T cell-mediated B cell responses, whether similar signaling mechanism exists in B cells has not been defined previously. Detre et al. (47) recently reported the role of SAP in modulating B cell functions. Because B cells do not express SAP, the mechanism by which SAP deficiency alters the B cell response is not clear. We observed no differences in SAP transcript levels in T and B cells (including Tfh cells and GC B cells) among B6, B6.Sle1b, and Sle1b-BAC90 mice. A recent study implicated the role of SAP-related molecule EAT-2 in mediating its effects in NK cells by linking SLAM family receptors to phospholipase Cg, calcium flux, and Erk kinase (48) . Whether signaling through this or other unknown adaptor molecules is compromised in B6.Sle1b B cells, resulting in lower calcium flux and reduced Erk phosphorylation, remains to be determined.
In summary, we showed that CD84 and Ly108 expression on GC B cells is critical for maintaining peripheral B cell tolerance at the GC checkpoint. Our data further highlight the importance of the GC pathway in autoimmune disease pathogenesis and suggest that GC B cell-specific CD84 and Ly108 may be therapeutic targets for systemic lupus erythematosus.
